AHIP executives discussed the impact the proposed budget bill could have on Medicaid and the individual market.

To deal with rising costs, employers are leveraging high performance networks, variable copay plans and exclusive provider ...

Over the past couple of years, ambient scribes have earned widespread adoption among health systems. While there's excitement ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

While fibrates are proven to lower triglyceride levels, which can serve as a biomarker for cardiovascular disease risk, several major clinical studies from the past 20 years have failed to show a ...

Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.

LLMs have opened a new world of possibilities regarding the care that patients can access and how they access it. For example, LLMs can be used to direct patients to the right level of care at the ...

When a hospital is thinking about beginning a tech pilot with a vendor, it really wants to know that the vendor is capable of understanding the various technological intricacies of the hospital ...

Alumis’s lead drug candidate blocks TYK2, an inflammation target that’s already addressed by Sotyktu, a Bristol Myers Squibb drug approved for plaque psoriasis.

The most pertinent pandemic threat today is the bird flu virus H5N1. Researchers around the world were alarmed when it began spreading among cattle in the U.S. last year. Cows are closer to humans ...

Andy Crowder, chief digital officer at Advocate Health, detailed five benefits his health system is experiencing as a result of being bullish on AI — including better staff retention, clinical ...

Alnylam Pharmaceuticals has landed a long-awaited FDA decision that expands use of its drug, Amvuttra, to the treatment of a type of cardiomyopathy that’s growing in prevalence.It’s the second ...